Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer
Philip C. Mack(UC Davis Comprehensive Cancer Center), Jorge Gómez(Icahn School of Medicine at Mount Sinai), Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), Ananda M. Rodilla(Universitat de Barcelona), Diego de Miguel‐Pérez(Mount Sinai Health System), Noy Meshulami(Icahn School of Medicine at Mount Sinai), Jacquelyn D. Treatman(Icahn School of Medicine at Mount Sinai), Chih–Yuan Hsu(Vanderbilt University Medical Center), Charles Gleason(Icahn School of Medicine at Mount Sinai), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Ariel Raskin(Icahn School of Medicine at Mount Sinai), Jennifer C. King(Go2 for Lung Cancer), Rachel Brody(Icahn School of Medicine at Mount Sinai), Sooyun Lee(Icahn School of Medicine at Mount Sinai), Christian Rolfo(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Amy Moore(LUNGevity Foundation)
Cited by 18
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
|New England Journal of Medicine|2021|803
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642